Nasdaq: IDXXIdexx Laboratories

    Idexx Laboratories Q3 2026 Results: Net Income $317 Million on Revenue of $1.21 Billion

    • US stocks
    • Earnings
    • Health Care
    A US one-dollar banknote standing upright on a white reflective surface in front of a white brick wall
    NeONBRAND neonbrand, via Wikimedia Commons (CC0). Illustrative image.

    Idexx Laboratories (Nasdaq: IDXX) reported GAAP revenue of $1.21 billion and GAAP net income of $317.1 million for the third quarter of 2026, and it said so on 2 Nov 2026. GAAP diluted EPS was $4.01 per share, and the company's comparable EPS, a non-GAAP measure, was $3.96.

    Key highlights

    • Revenue (GAAP): $1.21 billion, up 9.9% YoY and down 0.2% QoQ
    • Net income (GAAP): $317.1 million, up 15.5% YoY and down 6.3% QoQ
    • Diluted EPS (GAAP): $4.01, up 17.9% YoY
    • Operating margin (GAAP): 33.1%, up 1.0 percentage point YoY
    • Comparable EPS (company-defined, non-GAAP): $3.96

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue1,214.21,105.2+9.9%1,216.6-0.2%
    402.3354.8+13.4%425.6-5.5%
    317.1274.6+15.5%338.4-6.3%
    Diluted EPS ($)4.013.40+17.9%4.27-6.1%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table sets the release's GAAP figures for the third quarter of 2026 against the same quarter of 2025 and the second quarter of 2026. Revenue rose 9.9% from a year earlier, to $1.21 billion from $1.11 billion, and operating income rose 13.4%, to $402.3 million from $354.8 million.

    Against the previous quarter, revenue fell 0.2% and operating income fell 5.5%, and the operating margin was 1.8 percentage points lower. Net income was 26.1% of revenue, against 24.8% a year earlier.

    Comparable EPS is set below diluted EPS for the quarter

    Comparable EPS is a non-GAAP measure. The company listed three items in third quarter EPS: a $0.03 per share gain from a non-operating equity investment, a $0.01 share-based compensation tax benefit, and a $0.04 currency benefit. Its comparable EPS excludes the share-based compensation tax benefit and currency effects, and the release's reconciliation gives $3.96.

    Organic revenue growth was 10.0% in the quarter

    On an organic basis, revenue grew 10.0%, a non-GAAP measure that excludes currency and acquisitions. The company said Companion Animal Group revenue grew 10% as reported and organic, and CAG Diagnostics recurring revenue grew 11%.

    Outlook for 2026 revenue and EPS was raised

    The company now expects 2026 revenue of $4,741 million to $4,767 million, against a previous $4,700 million to $4,745 million. That includes $5 million related to the recent CoVet acquisition, according to the company.

    The company now expects EPS of $14.96 to $15.16, against $14.69 to $14.94 previously. It attributed the EPS increase to the raised revenue outlook, with acquisition impacts absorbed.

    The company lowered its reported operating margin outlook to 32.1% to 32.3%, from 32.3% to 32.5%, and said this includes acquisition-related impacts. Its comparable outlook excludes a $5 million unfavorable impact from a loss on an equity investment.

    Inference

    Idexx Laboratories bought back 199 thousand shares in the open market in the third quarter, at a cost of $111.8 million. Total cost of shares repurchased was $815.7 million in the nine months to 30 Sep 2026. Free cash flow of $420.8 million in the third quarter, a non-GAAP measure, and cash of $197.5 million at 30 Sep 2026 sit alongside those repurchases.

    The release does not say whether the EPS outlook is on a reported or comparable basis, or what the CoVet acquisition cost. The next dated event is a session for investors and analysts at VMX in Orlando, Florida, set for Monday, 18 Jan, at 1:00 p.m. ET.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts